Month: February 2024

Euroseas (ESEA) – December-quarter Results

Posted on by cpereira@noblefcm.com


Thursday, February 22, 2024

Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 140 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA. Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.

Michael Heim, Senior Vice President, Equity Research Analyst, Energy & Transportation, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Euroseas reported a 14% year-over-year increase in revenues, net during the quarter ended December 31, 2023 due mainly to the addition of a vessel and increased fleet utilization rates. Shipping rates were largely unchanged from last year and generally predictable given a high charter coverage.

Costs were generally in line with expectations. Drydocking expenses were higher than expected due to the retrofitting of the MV Synergy Busan. Interest and financing costs continue to rise with a $23 million year-over-year increase in debt as the company makes payments on six newbuilds. In total, the company is spending $220 million on the newbuilds with $65 million already paid and an additional $130 million to be financed. Bottom-line results were near expectations.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

The Runaway Growth of Nvidia Signals Big Opportunities for Investors in Tech

Posted on by slightbourne@noblecapitalmarkets.com

Nvidia’s meteoric rise over the past few years highlights the immense potential in tech for investors willing to bet on innovation. Revenue for the graphics chipmaker was up over 50% in 2021 alone, thanks to soaring demand for its AI, cloud computing, autonomous vehicle, and gaming technologies.

The company’s latest earnings release showed just how much it is dominating key growth markets – Q4 2022 revenue was up a staggering 410% for its data center segment driven by AI. Margins also expanded massively to 76%, exhibiting Nvidia’s ability to generate huge profits from the AI chip boom.

Experts point to Nvidia’s success as a sign that we’ve reached a tipping point for AI, with virtually every industry looking to incorporate these technologies. The market for AI is expected to reach hundreds of billions in value each year. Nvidia’s tech leadership has it positioned perfectly to ride this wave.

For investors, the rapid growth of Nvidia and other tech innovators signals enormous potential. The key is identifying tomorrow’s leaders in promising emerging tech sectors early before growth and valuations take off.

AI itself represents a massive opportunity – from autonomous driving to drug discovery to generative applications. Other sectors like robotics, blockchain, VR/AR, andquantum computing are likewise seeing surging interest and could produce the next Nvidias.

Savvy investors have a chance to get in early on smaller startups riding these trends. Finding the most innovative players with strong leadership and competitive advantages should be the focus.

Take AI chip startup SambaNova for example. With over $1 billion in funding, partnerships with Nvidia itself, and cutting-edge technology, it is making waves. Or intelligent robotics leader UiPath, which saw its valuation double to $37 billion since 2021 on booming demand.

These younger companies can prosper by carving out niche segments underserved by giants like Nvidia. With the right strategy and execution, huge returns are possible through acquisitions or public offerings.

However, risks are inherently high with unproven tech startups. Investors must diversify across enough emerging companies and accept that many will fail. Some may also get caught up in hype without real-world viability. But those that succeed could deliver multiples of whatever tech titans like Nvidia offer today.

The key is focusing on founders with real vision and avoiding overpriced valuations. But for investors with the risk tolerance, the bull market offers a prime moment to back potential hyper-growth tech winners early on.

Nvidia’s rise shows what can happen when transformative tech takes off. Opportunities abound to find the next Nvidia-like success if investors are willing to ride the wave of innovation in tech.

Novavax Stock Surges Over 20% on Positive Gavi Settlement

Posted on by slightbourne@noblecapitalmarkets.com

Shares of vaccine maker Novavax jumped over 20% on Thursday after the company announced it had reached a settlement agreement with Gavi, the Vaccine Alliance. The settlement resolves a dispute between the two organizations over a canceled COVID-19 vaccine order and provides a boost to the small cap pharmaceutical company.

In May 2021, Novavax signed an advance purchase agreement with Gavi for 350 million doses of its COVID vaccine. Gavi is a public-private global health partnership focused on increasing access to immunization in lower-income countries. It was planning to distribute Novavax’s shots globally through the COVAX initiative.

However, in 2022, Novavax terminated the agreement due to Gavi’s failure to procure any of the planned vaccine doses. Gavi sought a refund on $700 million in advance payments it had made to Novavax, but the company claimed these payments were non-refundable.

The dispute went to arbitration, with Gavi demanding full repayment of the $700 million in 2023. This presented a major financial risk for the small cap Novavax, which has a market capitalization under $5 billion.

Under the new settlement, Novavax will pay Gavi a total of up to $475 million, but in installments over 5 years. An initial $75 million payment has already been made. The remaining payments of $80 million annually through 2028 can potentially be reduced based on any future Novavax vaccine orders Gavi makes.

Gavi also has the option to order discounted Novavax vaccines over the next 5 years using “vaccine credits” provided under the settlement terms. This means that if demand arises, Novavax has the opportunity to supply more of its shots to Gavi for use in lower-income countries.

The flexible settlement terms are highly positive for Novavax’s business outlook. Instead of facing a risky $700 million payment in 2023, the company can spread payments over time while potentially recouping some of the amounts through future vaccine orders.

Many analysts viewed the Gavi arbitration as one of the largest overhangs on the beaten-down stock. Resolving this dispute eliminates a major uncertainty just as Novavax is struggling with low demand for its COVID vaccine. It also ensures Novavax can still participate in serving lower-income markets through partnerships like COVAX.

As a small cap player in the competitive vaccine space, Novavax relies heavily on such partnerships. The Gavi settlement provides the company with much-needed cash flow relief and keeps the door open to future deals. Novavax can now focus its resources on boosting sales and advancing other vaccines in its pipeline.

All told, the settlement comes as a major win for Novavax and its investors. While risks remain for the small vaccine developer, removing the Gavi arbitration cloud and securing continued market access is the optimistic boost Novavax needed right now. The company still faces challenges but has bought itself more time to strategically get back on track.

Take a look at more small cap biotech companies by taking a look at Noble Capital Markets’ Senior Research Analyst Robert LeBoyer’s coverage universe.

Fed in No Rush to Cut Rates While Inflation Remains Elevated

Posted on by slightbourne@noblecapitalmarkets.com

The minutes from the Federal Reserve’s latest Federal Open Market Committee (FOMC) meeting reveal a cautious stance by policymakers toward lowering interest rates this year, despite growing evidence of cooling inflation. The minutes underscored the desire by Fed officials to see more definitive and sustainable proof that inflation is falling steadily back towards the Fed’s 2% target before they are ready to start cutting rates. This patient approach stands in contrast to market expectations earlier in 2024 that rate cuts could begin as soon as March.

The deliberations detailed in the minutes point to several key insights into the Fed’s current thinking. Officials noted they have likely finished raising the federal funds rate as part of the current tightening cycle, with the rate now in a range of 4.5-4.75% after starting 2022 near zero. However, they emphasized they are in no rush to start cutting rates, wanting greater confidence first that disinflation trends will persist. Members cited the risks of easing policy too quickly if inflation fails to keep slowing.

The minutes revealed Fed officials’ desire to cautiously assess upcoming inflation data to judge whether the recent downward trajectory is sustainable and not just driven by temporary factors. This patient approach comes despite recent encouraging reports of inflation slowing. The latest CPI and PPI reports actually came in above expectations, challenging hopes of more decisively decelerating price increases.

Officials also noted the economy remains resilient with a strong job market. This provides the ability to take a patient stance toward rate cuts rather than acting preemptively. How to manage the Fed’s $8 trillion balance sheet was also discussed, but details were light, with further debate expected at upcoming meetings.

Moreover, policymakers stressed ongoing unease over still elevated inflation and the harm it causes households, especially more vulnerable groups. This reinforced their cautious posture of needing solid evidence of controlled inflation before charting a policy shift.

In response to the minutes, markets have significantly pushed back expectations for the Fed’s rate cut timeline. Traders are now pricing in cuts starting in June rather than March, with the overall pace of 2024 cuts slowing. The minutes align with recent comments from Fed Chair Jerome Powell emphasizing the need for sustained proof that inflationary pressures are abating before rate reductions can begin.

The minutes highlight the tricky position the Fed faces in navigating policy uncertainty over how quickly inflation will decline even after aggressive 2023 rate hikes. Officials debated incoming data signals of potentially transitory inflation reductions versus risks of misjudging and overtightening policy. With the economy expanding solidly for now, the Fed has the leeway to be patient and avoid premature policy loosening. But further volatility in inflation readings could force difficult adjustments.

Looking ahead, markets will be hyper-focused on upcoming economic releases for evidence that could support a more decisive pivot in policy. Any signs of inflation slowing convincingly toward the Fed’s 2% goal could boost rate cut bets. Yet with labor markets and consumer demand still resilient, cooling inflation to the Fed’s satisfaction may take time. The minutes clearly signaled Fed officials will not be rushed into lowering rates until they are fully convinced price stability is sustainably taking hold. Their data-dependent approach points to a bumpy path ahead for markets.

AstraZeneca Completes $1.1 Billion Buyout of Seattle Biotech Icosavax

Posted on by slightbourne@noblecapitalmarkets.com

UK pharmaceutical giant AstraZeneca has finalized its $1.1 billion acquisition of Icosavax, a Seattle-based biotechnology company specializing in virus-like particle (VLP) vaccines. This buyout provides key insights into AstraZeneca’s pipeline strategy and the ongoing consolidation in the biopharma sector.

Icosavax was founded in 2017 as a spinout from the University of Washington’s Institute for Protein Design. The company leverages computationally designed VLPs to induce robust and durable immune responses against respiratory viruses, including COVID-19, respiratory syncytial virus (RSV), and human metapneumovirus (hMPV).

Since its founding, Icosavax has raised over $150 million in private funding and completed a successful IPO in 2021. However, the company caught the eye of pharma giant AstraZeneca, who sees Icosavax’s VLP platform and talented research team as a strategic fit.

For AstraZeneca, this acquisition provides access to a versatile new vaccine modality with broad applicability beyond Icosavax’s current clinical programs. It also bolsters AstraZeneca’s pipeline with a Phase 1/2 COVID-19 vaccine candidate, IVX-411, which produced robust neutralizing antibody titers in early clinical testing.

Broader Implications for Investors and the Biopharma Industry

The buyout has several key implications for biotech investors and industry dynamics. Firstly, it highlights that platform technologies with versatile applications across disease areas remain highly valued, even in the ongoing biotech market downturn. Vaccines also continue to see strong corporate interest after the pandemic spotlight.

Secondly, it reflects Big Pharma’s pursuit of emerging biotech innovation to replenish pipelines and access cutting-edge modalities like VLPs. With the Icosavax deal, AstraZeneca gains talented scientists and potential new products without costly in-house R&D.

Thirdly, from a structure standpoint, the deal provides an upfront cash payout to Icosavax investors but leaves upside through future contingent payments on pipeline advancement. This highlights a flexible model to balance the high valuations sought by biotechs with the risk management needs of acquirers.

Finally, the buyout continues the wave of consolidation between large and small biopharma players. With the market downturn squeezing biotech funding, more mergers and acquisitions are likely on the horizon. Investors should watch for other innovative biotechs with promising science that become acquisition targets.

What Drove AstraZeneca’s Interest in Icosavax

AstraZeneca has been one of the more active Big Pharmas on the M&A front, and the Icosavax deal provides strategic rationale. The VLP technology adds a promising new platform to AstraZeneca’s vaccine capabilities, already bolstered by its previous acquisitions of drug delivery player MedImmune and biotech Sobi.

Icosavax’s potential COVID-19 and RSV vaccine candidates can be added to AstraZeneca’s pipeline as it looks to expand beyond its core oncology portfolio. Additionally, Icosavax’s team and VLP engineering expertise will be valuable assets for the company.

By acquiring Icosavax while still early-stage compared to more established biopharmas, AstraZeneca secures access to the technology at a reasonable price. The $1.1 billion price tag is well below the multi-billion deals that some commercial-stage biotechs have commanded.

Overall, Icosavax represented an opportunity for AstraZeneca to obtain cutting-edge vaccine technology and talent to boost its R&D capabilities in new directions. It highlights that Big Pharmas are willing to buy innovation at early stages rather than develop it internally.

Take a moment to take a look at emerging growth healthcare and biotech companies by taking a look at Noble Capital Markets’ Senior Research Analyst Robert LeBoyers’s coverage universe

The Future for Icosavax’s Programs

While the buyout places Icosavax’s pipeline under AstraZeneca’s control, active development of the VLP programs is expected to continue. Lead COVID-19 vaccine candidate IVX-411 recently began Phase 1/2 trials, and its RSV and hMPV programs are progressing towards clinical stages as well.

AstraZeneca has expressed interest in advancing Icosavax’s full portfolio of vaccines leveraging the versatility of the VLP platform. Its resources and late-stage development expertise can help progress these experimental vaccines through clinical trials and regulatory approval pathways.

Meanwhile, Icosavax will continue operations as an AstraZeneca subsidiary based in Seattle. Keeping its operations separate allows Icosavax to retain its innovative biotech culture while benefiting from AstraZeneca’s financial backing and synergies.

In summary, AstraZeneca’s acquisition of Icosavax underscores its strategy of looking to smaller biotechs to supplement its pipeline with cutting-edge science. The deal rewards Icosavax investors for their early backing while retaining upside potential through milestone payments. For the biopharma industry, it exemplifies the ongoing consolidation between pharmas and biotechs amidst market pressures. Investors should watch for other emerging biotechs that may become tomorrow’s M&A targets.

Release – Hemisphere Energy Recognized as Top 50 TSX Venture Exchange Company

Posted on by aweinsoff@channelchek.com

Research News and market Data on HMENF

February 21, 2024 7:30 AM EST | Source: Hemisphere Energy Corporation

Vancouver, British Columbia–(Newsfile Corp. – February 21, 2024) – Hemisphere Energy Corporation (TSXV: HME) (OTCQX: HMENF) (“Hemisphere” or the “Company”) is pleased to announce that it has been named as one of the top performers on the TSX Venture Exchange (“TSXV”) for the third consecutive year.

The 2024 TSXV 50 showcases the top 50 of over 1,600 TSXV issuers across five sectors: energy, mining, clean technology, life sciences, diversified industries, and technology. The ranking is an equal weighting of each company’s performance during 2023 across three key indicators: market capitalization growth, share price appreciation, and trading volume. More details can be found at the following link: www.tsx.com/venture50.

“We are proud to earn a ranking on the 2024 TSXV Venture 50 list for the third consecutive year,” said Don Simmons, President and Chief Executive Officer of Hemisphere. “The Company has continued to take great strides in growing its operations over the past year while maintaining a strong balance sheet and focusing heavily on return of capital to its shareholders.”

About Hemisphere Energy Corporation

Hemisphere is a dividend-paying Canadian oil company focused on maximizing value per share growth with the sustainable development of its high netback, low decline conventional heavy oil assets through polymer flood enhanced recovery methods. Hemisphere trades on the TSX Venture Exchange as a Tier 1 issuer under the symbol “HME” and on the OTCQX Venture Marketplace under the symbol “HMENF”.

For further information, please visit the Company’s website at www.hemisphereenergy.ca to view its corporate presentation or contact:

Don Simmons, President & Chief Executive Officer
Telephone: (604) 685-9255
Email: info@hemisphereenergy.ca
Website: www.hemisphereenergy.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: Hemisphere Energy Corporation

Seanergy Maritime (SHIP) – December-quarter preview

Posted on by cpereira@noblefcm.com


Wednesday, February 21, 2024

Seanergy Maritime Holdings Corp. is the only pure-play Capesize ship-owner publicly listed in the US. Seanergy provides marine dry bulk transportation services through a modern fleet of Capesize vessels. The Company’s operating fleet consists of 17 Capesize vessels with an average age of approximately 12 years and aggregate cargo carrying capacity of approximately 3,011,083 dwt. The Company is incorporated in the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP” and its Class B warrants under “SHIPZ”.

Michael Heim, Senior Vice President, Equity Research Analyst, Energy & Transportation, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Shipping rates improved at the end of the quarter. At the end of the third quarter, management indicated that it had locked in 60% of estimated operating days at $21,640/day and that at current spot prices, the average TCE rate for the quarter would be $19,480/day. With spot prices rising, the average TCE rate will most likely be closer to $23,000/day. The addition of a new vessel and limited drydocking will mean increased operating days. Raising the TCE rate in our models increase revenues by approximately $4 million.

Shipping rates have fallen in the 2024-1Q due to seasonal factors such as the Chinese New Year and the rain season in Brazil but remain above historical 1Q levels. We have lowered our revenue projection to reflect lower rates and decreased fees from related parties (Seanergy receives revenues for third party ship management which included abnormal gains in 2023-3Q). 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Orion Group Holdings (ORN) – A Contract for East West Jones?

Posted on by cpereira@noblefcm.com


Wednesday, February 21, 2024

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A New Contract. Yesterday, after the market close, Orion filed an 8-K disclosing the entry into a sales contract for its 340 acre East West Jones land parcels previously used by the Company as dredge placement areas. The purchase price is approximately $34 million and closing is anticipated on or before June 14, 2024.

A Modest Reduction. This is not the first time Orion has entered into a transaction for the property. Back in April 2023, Orion entered into a contract to sell the parcels for approximately $36 million. While the $2 million reduction in the sales price is not optimal, we view the monetization of another non-core asset to be a positive.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

FAT Brands (FAT) – Company Receives Wells Notice

Posted on by cpereira@noblefcm.com


Wednesday, February 21, 2024

FAT Brands (NASDAQ: FAT) is a leading global franchising company that strategically acquires, markets, and develops fast casual, quick-service, casual dining, and polished casual dining concepts around the world. The Company currently owns 17 restaurant brands: Round Table Pizza, Fatburger, Marble Slab Creamery, Johnny Rockets, Fazoli’s, Twin Peaks, Great American Cookies, Hot Dog on a Stick, Buffalo’s Cafe & Express, Hurricane Grill & Wings, Pretzelmaker, Elevation Burger, Native Grill & Wings, Yalla Mediterranean and Ponderosa and Bonanza Steakhouses, and franchises and owns over 2,300 units worldwide. For more information on FAT Brands, please visit www.fatbrands.com.

Joe Gomes, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Wells Notice. In an 8-K filed yesterday, FAT Brands reported that the Company, Chairman Andrew Wiederhorn, and one current and one former officer of the Company each received a Wells Notice from the staff of the SEC. The notice is related to the previously disclosed SEC investigation of the Company. The Company continues to cooperate with the SEC and maintains its actions were appropriate, and intends to pursue the Wells Notice process, including submitting a formal response to the SEC.

What Is a Wells Notice? According to the Cornell Law School Legal Information Institute, “A ‘Wells Notice’ is a letter sent by a securities regulator to a prospective respondent, notifying him of the substance of charges that the regulator intends to bring against the respondent, and affording the respondent with the opportunity to submit a written statement to the ultimate decision maker.”


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Uranium’s Breakout Above $100/lb Signals Further Bull Run Ahead

Posted on by slightbourne@noblecapitalmarkets.com

The uranium spot price has crossed a major threshold, surging past $100/lb in January 2024 to reach $106.51/lb in early February. This long-awaited milestone marks the first time uranium has hit triple digits since the bull run leading up to the 2008 financial crisis.

The implications of breaching $100/lb are significant for the uranium market. Prices at this level indicate the serious supply and demand imbalances that have characterized the market for years are finally coming to a head. With demand outpacing available supply from mines, traders see uranium poised for further gains still.

The main driver behind January’s price spike was a cut to production forecasts from Kazatomprom, the world’s largest uranium miner. The company stunned the market by announcing lower guidance for 2024 and 2025 due to shortages of a key chemical and construction delays. This reversal came just months after Kazatomprom had planned to boost output to meet rising demand. The supply uncertainty led uranium prices to immediately jump over 8%.

For investors, Kazatomprom’s about-face signals that the supply response to uranium’s bull run may proceed slower than expected. Mine expansions and restarts are lagging, with not enough incentive yet for substantial new production. The supply picture is further complicated by uncertainty around Niger’s uranium exports following a coup there last year.

Junior uranium miners have been the biggest winners from the bullish momentum. With less exposure to long-term contracts than larger producers, juniors are benefiting from the full upside of rising spot prices. Many have announced restarts of idled capacity to take advantage of the favorable pricing environment. Their outsized gains indicate investors see juniors playing a key role in bridging future supply shortfalls.

Reaching the $100/lb mark is a psychological victory for uranium bulls who have waited years for prices to reflect positive fundamentals. Nuclear energy demand is on the rise again amid its role in carbon-free baseload power. With most forecast models predicting large supply deficits opening up over the next decade, there is a growing sense $100/lb is just the beginning.

Past experience shows reaching this triple-digit territory is when utilities truly start getting worried about security of supply. The last time uranium crossed above $100/lb in 2007, it sparked a frenzy of long-term contracting not seen before or since. While contracting volumes picked up last year, they remain below levels to fully cover global reactor requirements.

Many see $100/lb as the price needed to incentivize meaningful new mine production. Bringing large-scale conventional projects online takes over a decade when factoring in permitting and construction. Even smaller ISR operations can take several years to expand. With demand projected to outstrip supply for years to come, prices above $100/lb may be the new normal rather than an unsustainable spike.

For investors, uranium crossing $100/lb should serve as a wake-up call that a structural bull market is unfolding. Uranium has significantly outperformed most other commodity sectors over the past several years. With demand still rising and enormous lead times for new projects, supply shortfalls won’t be reversed overnight.

Now is the time for investors to gain exposure before uranium potentially keeps running toward new highs. Uranium equities offer upside well beyond movements in the underlying commodity price. Juniors in particular stand to see valuations explode higher if they can continue locking in contracts above $100/lb.

While nothing moves up forever, the fundamentals underpinning uranium’s surge past $100/lb look here to stay. Nuclear reactors need reliable fuel supply. Achieving net-zero carbon emissions globally depends on nuclear generation ramping up. With mines struggling to keep pace, all signs point to the uranium bull market having ample room left to run at these levels and beyond.

XOMA to Acquire Kinnate Biopharma in All-Cash Buyout Deal

Posted on by slightbourne@noblecapitalmarkets.com

Biotech royalty company XOMA Corporation (NASDAQ: XOMA) has entered an agreement to fully acquire clinical-stage oncology firm Kinnate Biopharma Inc. (NASDAQ: KNTE) in an all-cash deal valued up to $150 million.

This bold acquisition provides XOMA an opportunity to expand its cancer drug royalty portfolio while handing Kinnate shareholders an immediate payday.

For XOMA, the deal delivers two key benefits:

First, it stands to add approximately $9.5 million in cash to the balance sheet, providing extra fuel for future investments and deal-making.

But more importantly, it grants XOMA rights to Kinnate’s pipeline of early-stage oncology candidates. These experimental drugs, if eventually approved, could generate lucrative milestone and royalty payments for XOMA down the road.

Kinnate’s leading assets are two precision medicines in Phase 1 testing – an FGFR inhibitor for cancers driven by FGFR mutations and a pan-RAF inhibitor targeting BRAF and NRAS mutant tumors. Both therapies show promise in initial trials, with additional data expected later this year.

Beyond these advanced assets, Kinnate also boasts alluring preclinical programs in areas like CDK4 inhibition and c-MET inhibition.

For a royalty collector like XOMA, acquiring rights to future royalties on these promising cancer compounds is a savvy move. XOMA’s expertise is striking licensing and royalty deals with biopharma partners. Adding Kinnate’s pipeline to its war chest provides ample new opportunities to flex this deal-making muscle.

And XOMA has a proven track record here. Its lucrative sale last year of royalty rights to the Novartis drug VABYSMO generated over half a billion in cash proceeds. Funneling the proceeds into new royalty streams helps ensure consistent future revenues.

On the flip side, the buyout delivers Kinnate shareholders a decent return amid a downtrodden biotech market. The deal’s maximum price of $2.5879 per share only carries a modest 7% premium over Kinnate’s recent average share price.

But with small-cap biotech valuations crushed across the board, it allows Kinnate investors to cash out at favorable terms compared to remaining standalone. After announcing plans to merge with an unrelated freight company, receiving a buyout provides a more attractive outcome.

Shareholders also retain some upside through CVRs granting them proceeds from any deal for Kinnate’s programs in the year post-buyout.

Importantly, insiders holding nearly half of Kinnate’s shares have signed agreements to tender their stock. This influential support should pave the way to completing the acquisition.

The proposed deal checks all the boxes. XOMA diversifies its royalty portfolio, Kinnate shareholders get paid at a premium, and the cancer drugs have a new catalyst to advance development.

Sometimes simple deals done for the right reasons benefit everyone involved. This cash buyout looks to be just such a win-win-win transaction.

noble virtual healthcare conference

Mark your calendars! Don’t miss Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on April 17-18. This exclusive virtual event connects investors with 50 leading public biotech, healthcare services, and medical device companies. Presenting company slots are available…Read More

Release – Xcel Brands Announces Participation In Noble Capital Markets C-Suite Interview Series

Posted on by aweinsoff@channelchek.com

Research News and Marketing Data on XELB


February 20, 2024 at 8:00 AM EST

PDF Version

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB), a media and consumer products company with expertise in livestream shopping and social commerce, announced their participation in Noble Capital Markets’ C-Suite Interview Series, presented by Channelchek.

Xcel Brands CEO, Robert D’Loren, sat down with Noble Capital Markets Senior Research, Michael Kupinski, for this exclusive two-part series. Topics covered include:

  • Part one, Xcel Brands CEO Robert D’Loren provides a corporate overview, discussing Xcel’s core business model, their brands, key revenue figures, current financial outlook, and their new e-commerce platform, ORME. Learn more on Xcel Brands here.
  • Part two highlights the launch of ORME, a next generation short form video marketplace, which will become a game changer in the social influencer marketplace. Learn more on ORME here.

The interview was recorded on February 1, 2024, and is available now on Channelchek.

About Xcel Brands

Xcel Brands, Inc. (NASDAQ: XELB) is a media and consumer products company engaged in the design, marketing, live streaming, social commerce sales of branded apparel, footwear, accessories, fine jewelry, home goods and other consumer products, and the acquisition of dynamic consumer lifestyle brands. Xcel was founded in 2011 with a vision to reimagine shopping, entertainment, and social media as one thing. Xcel owns the Judith Ripka, Halston, LOGO by Lori Goldstein, and C. Wonder by Christian Siriano brands and a minority stake in the Isaac Mizrahi brand. It also owns and manages the Longaberger brand through its controlling interest in Longaberger Licensing LLC and a 50% interest in a JV in TWRHLL (“Tower Hill”) by Christie Brinkley. Xcel is pioneering a true modern consumer products sales strategy which includes the promotion and sale of products under its brands through interactive television, digital live-stream shopping, social commerce, brick-and-mortar retail, and e-commerce channels to be everywhere its customer’s shop. The company’s brands have generated in excess of $4 billion in retail sales via livestreaming in interactive television and digital channels alone. Headquartered in New York City, Xcel Brands is led by an executive team with significant live streaming, production, merchandising, design, marketing, retailing, and licensing experience, and a proven track record of success in elevating branded consumer products companies. www.xcelbrands.com. 

About ORME

ORME is based in New York and is a next generation short form video marketplace inspiring our users through honest and authentic content created by shoppers, creators, influencers and brands wherever they create, watch, listen, connect and socialize in the digital universe. ORME was cofounded by Xcel Brands and KonnectBio, Inc.

ORME is committed to evolving through innovations in technology including the major application of AI, making deep connections with our users and community and providing opportunity to all in the retail commerce flywheel. ORME makes the everyday shopper a paid influencer. www.ormelive.com

About Noble Capital Markets

Noble Capital Markets, Inc. was incorporated in 1984 as a full-service SEC / FINRA registered broker-dealer, dedicated exclusively to serving underfollowed small / microcap companies through investment banking, wealth management, trading & execution, and equity research activities. Over the past 37 years, Noble has raised billions of dollars for these companies and published more than 45,000 equity research reports. www.noblecapitalmarkets.com email: contact@noblecapitalmarkets.com

About Channelchek

Channelchek (.com) is a comprehensive investor-centric portal – featuring more than 6,000 emerging growth companies – that provides advanced market data, independent research, balanced news, video webcasts, exclusive c-suite interviews, and access to virtual road shows. The site is available to the public at every level without cost or obligation. Research on Channelchek is provided by Noble Capital Markets, Inc., an SEC / FINRA registered broker-dealer since 1984. www.channelchek.com email: contact@channelchek.com

Source: Xcel Brands, Inc

Release – Kratos Orders Nine Zeus 1 and Zeus 2 Rocket Motors in Preparation for Initial Customer Funded Flights

Posted on by aweinsoff@channelchek.com

Research News Market Data on KTOS

February 20, 2024 at 8:00 AM EST

PDF Version

ZEUS 1 Static Fire

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/caf8484b-861c-4384-9be9-292269a2f75a

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) —  Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a Technology Company in Defense, National Security and Global Markets announced today that its Space & Missile Defense (SMDS) business unit has ordered a combined total of nine new Zeus 1 and Zeus 2 rocket motors in preparation for upcoming initial customer funded flights. The Kratos developed Zeus family of Solid Rocket Motors (SRMs) is in direct response to the urgent need for affordable commercial launch vehicle stages for hypersonic test, ballistic missile target, sounding rocket and “other” customer missions.  SMDS applied its significant experience to establish the Zeus 1 and Zeus 2 motor requirements and specifications in close coordination with respective customer and user communities. Kratos, through internal investments, funded development of the Zeus SRMs which are designed and manufactured to Kratos’ specifications by key merchant supplier and partner, Aerojet Rocketdyne.

The Kratos Zeus 1 and Zeus 2 SRMs provide substantial performance improvements over similar legacy and heritage SRMs within the same relevant form factor, allowing existing vehicle designs and launch infrastructure to remain unchanged while also promoting rapid integration of leading technology systems and payloads, including those currently under development by Kratos. These and other key attributes will provide Kratos’ customers opportunities to fly more often, faster and farther, using fewer stages, at a substantially reduced cost.

The Zeus 1 and Zeus 2 are high-performance 32.5-inch diameter SRMs, designed with versatility and affordability in mind as a complement to Kratos’ internally funded investments in the Erinyes hypersonic test “flyer” that is expected to debut later this year. Kratos Zeus SRMs will also complement Kratos’ internally funded, follow-on Dark Fury hypersonic system, which nature and performance characteristics are highly classified. These Kratos investments in the hypersonic and other relevant areas create a versatile family of test, evaluation and “other” products that offer complete systems, SRMs, and flyers. With the Zeus SRMs, and the Erinyes, Dark Fury, and other Kratos front ends, Kratos is one of the only companies boasting both launcher and “Flyer” systems within one organization, providing unmatched innovation, disruptive capabilities, mission responsiveness and affordability to the customer.

Dave Carter, President of Kratos Defense & Rocket Support Services Division, said, “The Kratos Zeus family of SRMs is representative of our strategy to internally fund, rapidly develop, be first to market and field affordable, relevant systems to the United States Department of Defense and our Allies. At Kratos, affordability is a technology, and the low cost of these incredibly effective, high-performance systems, is driving significant interest from the relevant customer and user communities, as represented by this initial order of Zeus SRMs.”

Eric DeMarco, President and CEO of Kratos, said, “Kratos Zeus family of SRMs demonstrates our internally funded investment strategy of delivering relevant products and systems, not power points or renditions, to the National Security market. Kratos Zeus family of motors, similar to other Kratos systems, including tactical drones like Valkyrie, our Oriole rocket, and our hypersonic flyers Erinyes and Dark Fury, are not only rapidly developed and demonstrated, but are also engineered up front for affordable mass production at quantity, an additional Kratos differentiator and value enhancer for our government customers and also for our traditional prime system integrator partners.”

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets.  Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements.  At Kratos, affordability is a technology, and we seek to utilize proven, leading edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions.  We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low cost future manufacturing which is a value add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers.  Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter.  For more information, visit www.KratosDefense.com

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 31, 2023, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Kratos Press Contact:
Yolanda White
858-812-7302 Direct

Kratos Investor Information:
877-934-4687
investor@kratosdefense.com